Molecular mechanisms and clinical tapering strategies for Janus kinase inhibitor relapse in inflammatory dermatoses
Janus kinase (JAK) inhibitors have revolutionized the management of inflammatory dermatoses over recent decades; however, discontinuation is frequently associated with rapid disease recurrence, known as the “relapse” phenomenon, which complicates long-term disease control. Current evidence on the molecular pathophysiol...